<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Transl Psychiatry</journal-id>
<journal-id journal-id-type="iso-abbrev">Transl Psychiatry</journal-id>
<journal-title-group>
<journal-title>Translational Psychiatry</journal-title>
</journal-title-group>
<issn pub-type="epub">2158-3188</issn>
<publisher>
<publisher-name>Nature Publishing Group UK</publisher-name>
<publisher-loc>London</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">31712584</article-id>
<article-id pub-id-type="pmc">6848075</article-id>
<article-id pub-id-type="publisher-id">641</article-id>
<article-id pub-id-type="doi">10.1038/s41398-019-0641-0</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Modulation of brain activation during executive functioning in autism with citalopram</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-6630-8038</contrib-id>
<name>
<surname>Wichers</surname>
<given-names>Robert H.</given-names>
</name>
<address>
<phone>+44 207 848 0947</phone>
<email>rob.wichers@kcl.ac.uk</email>
</address>
<xref ref-type="aff" rid="Aff1">1</xref>
<xref ref-type="aff" rid="Aff2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Findon</surname>
<given-names>James L.</given-names>
</name>
<xref ref-type="aff" rid="Aff1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Jelsma</surname>
<given-names>Auke</given-names>
</name>
<xref ref-type="aff" rid="Aff1">1</xref>
<xref ref-type="aff" rid="Aff3">3</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-9381-8201</contrib-id>
<name>
<surname>Giampietro</surname>
<given-names>Vincent</given-names>
</name>
<xref ref-type="aff" rid="Aff4">4</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Stoencheva</surname>
<given-names>Vladimira</given-names>
</name>
<xref ref-type="aff" rid="Aff2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Robertson</surname>
<given-names>Dene M.</given-names>
</name>
<xref ref-type="aff" rid="Aff1">1</xref>
<xref ref-type="aff" rid="Aff2">2</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-6350-0155</contrib-id>
<name>
<surname>Murphy</surname>
<given-names>Clodagh M.</given-names>
</name>
<xref ref-type="aff" rid="Aff1">1</xref>
<xref ref-type="aff" rid="Aff2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>McAlonan</surname>
<given-names>Grainne</given-names>
</name>
<xref ref-type="aff" rid="Aff1">1</xref>
<xref ref-type="aff" rid="Aff2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Ecker</surname>
<given-names>Christine</given-names>
</name>
<xref ref-type="aff" rid="Aff5">5</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Rubia</surname>
<given-names>Katya</given-names>
</name>
<xref ref-type="aff" rid="Aff6">6</xref>
</contrib>
<contrib contrib-type="author" equal-contrib="yes">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-6664-7451</contrib-id>
<name>
<surname>Murphy</surname>
<given-names>Declan G. M.</given-names>
</name>
<xref ref-type="aff" rid="Aff1">1</xref>
<xref ref-type="aff" rid="Aff2">2</xref>
</contrib>
<contrib contrib-type="author" equal-contrib="yes">
<name>
<surname>Daly</surname>
<given-names>Eileen M.</given-names>
</name>
<xref ref-type="aff" rid="Aff1">1</xref>
</contrib>
<aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2322 6764</institution-id><institution-id institution-id-type="GRID">grid.13097.3c</institution-id><institution>Department of Forensic and Neurodevelopmental Sciences, The Sackler Centre for Translational Neurodevelopment, </institution><institution>Institute of Psychiatry, Psychology and Neuroscience, King’s College London, </institution></institution-wrap>London, UK </aff>
<aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0000 9439 0839</institution-id><institution-id institution-id-type="GRID">grid.37640.36</institution-id><institution>Behavioural and Developmental Psychiatry Clinical Academic Group, </institution><institution>South London and Maudsley NHS Trust, </institution></institution-wrap>London, UK </aff>
<aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0435 165X</institution-id><institution-id institution-id-type="GRID">grid.16872.3a</institution-id><institution>VU University Medical Center, </institution></institution-wrap>Amsterdam, The Netherlands </aff>
<aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2322 6764</institution-id><institution-id institution-id-type="GRID">grid.13097.3c</institution-id><institution>Department of Neuroimaging, Institute of Psychiatry, Psychology and Neuroscience, </institution><institution>King’s College London, </institution></institution-wrap>London, UK </aff>
<aff id="Aff5"><label>5</label>Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, University Hospital Frankfurt am Main, Goethe-University Frankfurt am Main, Frankfurt, Germany </aff>
<aff id="Aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2322 6764</institution-id><institution-id institution-id-type="GRID">grid.13097.3c</institution-id><institution>Department of Child &amp; Adolescent Psychiatry, Institute of Psychiatry, </institution><institution>Psychology and Neuroscience, King’s College London, </institution></institution-wrap>London, UK </aff>
</contrib-group>
<pub-date pub-type="epub">
<day>11</day>
<month>11</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>11</day>
<month>11</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="collection">
<year>2019</year>
</pub-date>
<volume>9</volume>
<elocation-id>286</elocation-id>
<history>
<date date-type="received">
<day>19</day>
<month>7</month>
<year>2019</year>
</date>
<date date-type="accepted">
<day>1</day>
<month>8</month>
<year>2019</year>
</date>
</history>
<permissions>
<copyright-statement>© The Author(s) 2019</copyright-statement>
<license license-type="OpenAccess">
<license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p>
</license>
</permissions>
<abstract id="Abs1">
<p id="Par1">Adults with autism spectrum disorder (ASD) are frequently prescribed selective serotonin reuptake inhibitors (SSRIs). However, there is limited evidence to support this practice. Therefore, it is crucial to understand the impact of SSRIs on brain function abnormalities in ASD. It has been suggested that some core symptoms in ASD are underpinned by deficits in executive functioning (EF). Hence, we investigated the role of the SSRI citalopram on EF networks in 19 right-handed adult males with ASD and 19 controls who did not differ in gender, age, IQ or handedness. We performed pharmacological functional magnetic resonance imaging to compare brain activity during two EF tasks (of response inhibition and sustained attention) after an acute dose of 20 mg citalopram or placebo using a randomised, double-blind, crossover design. Under placebo condition, individuals with ASD had abnormal brain activation in response inhibition regions, including inferior frontal, precentral and postcentral cortices and cerebellum. During sustained attention, individuals with ASD had abnormal brain activation in middle temporal cortex and (pre)cuneus. After citalopram administration, abnormal brain activation in inferior frontal cortex was ‘normalised’ and most of the other brain functional differences were ‘abolished’. Also, within ASD, the degree of responsivity in inferior frontal and postcentral cortices to SSRI challenge was related to plasma serotonin levels. These findings suggest that citalopram can ‘normalise’ atypical brain activation during EF in ASD. Future trials should investigate whether this shift in the biology of ASD is maintained after prolonged citalopram treatment, and if peripheral measures of serotonin predict treatment response.</p>
</abstract>
<kwd-group kwd-group-type="npg-subject">
<title>Subject terms</title>
<kwd>Molecular neuroscience</kwd>
<kwd>Predictive markers</kwd>
</kwd-group>
<funding-group>
<award-group>
<funding-source>
<institution>European Autism Interventions - A Multicentre Study for Developing New Medications (EU-AIMS) (receiving support from the Innovative Medicines Initiative Joint Undertaking under grant agreement 115300, which includes financial contributions from the EU Seventh Framework Programme [FP7/2007–2013] and from the European Federation of Pharmaceutical Industries and Associations), a grant from EU-AIMS-2-TRIALS (to Prof. D.G. Murphy), a grant (to Prof. D.G Murphy) from NIHR Mental Health Biomedical Research Centre Infrastructure Support for Pilot Studies and a grant (to Prof. D.G Murphy) from the Sackler Institute for Translational Neurodevelopment.</institution>
</funding-source>
</award-group>
</funding-group>
<custom-meta-group>
<custom-meta>
<meta-name>issue-copyright-statement</meta-name>
<meta-value>© The Author(s) 2019</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
</front>
<body>
<sec id="Sec1" sec-type="introduction">
<title>Introduction</title>
<p id="Par2">Autism spectrum disorder (ASD) is a neurodevelopmental condition that is characterised by social communication deficits and repetitive or stereotypical behaviours<sup><xref ref-type="bibr" rid="CR1">1</xref></sup>. It has been estimated that 29% of individuals with ASD in the UK are prescribed psychotropic medications<sup><xref ref-type="bibr" rid="CR2">2</xref></sup>. Antidepressants, mainly selective serotonin reuptake inhibitors (SSRIs), are prescribed in 6% of people with ASD in the UK<sup><xref ref-type="bibr" rid="CR2">2</xref></sup>, and are the fourth most commonly prescribed psychotropic drugs worldwide in adults with ASD<sup><xref ref-type="bibr" rid="CR3">3</xref></sup>. SSRIs are normally prescribed for mood and anxiety disorders, which are highly prevalent (26–57% and 29–54%, respectively<sup><xref ref-type="bibr" rid="CR4">4</xref>–<xref ref-type="bibr" rid="CR7">7</xref></sup>) in ASD. For this practice is, to the best of our knowledge, currently no available evidence. There is, however, a small body of work suggesting that SSRIs are effective in treating core symptoms in adults with ASD. For instance, two studies of fluoxetine reported significant reductions in repetitive behaviours<sup><xref ref-type="bibr" rid="CR8">8</xref>,<xref ref-type="bibr" rid="CR9">9</xref></sup>. One study of fluvoxamine in adults with ASD also reported a reduction in repetitive behaviours as well as improvement of social communication<sup><xref ref-type="bibr" rid="CR10">10</xref></sup>. However, these studies included limited sample sizes and the reported benefits were small in comparison to placebo. This indicates that clinical trials are needed to further investigate the effectiveness of SSRIs in adults with ASD, especially as there are currently no pharmacological treatments approved by the Food &amp; Drug Administration (FDA) for treating core symptoms. However, clinical trials have become increasingly expensive<sup><xref ref-type="bibr" rid="CR11">11</xref></sup>, most trials in neuropsychiatric disorders fail, and so industry is investing less in neuroscience. Therefore, it is crucial that we first provide ‘proof of concept’ that potential treatments (e.g. SSRIs) can impact on abnormalities in brain functions associated with core symptoms. Moreover, it has been proposed that core symptoms are partially underpinned by deficits in executive functioning (EF) in ASD<sup><xref ref-type="bibr" rid="CR12">12</xref>,<xref ref-type="bibr" rid="CR13">13</xref></sup>. Therefore, EF networks may provide novel treatment targets and/or an early ‘read out’ of potential efficacy.</p>
<p id="Par3">Executive functioning comprises a range of cognitive processes that are required when concentrating and paying and/or switching attention<sup><xref ref-type="bibr" rid="CR14">14</xref></sup>. Individuals with ASD have been reported to have difficulties in performing EF tasks. For example, poorer performance has been reported in adults with ASD compared to controls during performance of a response inhibition task<sup><xref ref-type="bibr" rid="CR15">15</xref></sup> and in children and adults during performance of sustained attention tasks<sup><xref ref-type="bibr" rid="CR16">16</xref>,<xref ref-type="bibr" rid="CR17">17</xref></sup>. Additionally, functional MRI studies have demonstrated abnormal brain activation in children and adults with ASD as compared to controls during response inhibition<sup><xref ref-type="bibr" rid="CR18">18</xref>,<xref ref-type="bibr" rid="CR19">19</xref></sup> and sustained attention tasks<sup><xref ref-type="bibr" rid="CR16">16</xref>,<xref ref-type="bibr" rid="CR20">20</xref></sup>. The biological basis of this is poorly understood but may include the serotonergic system, which is involved in motor inhibition<sup><xref ref-type="bibr" rid="CR21">21</xref></sup> as well as sustained attention<sup><xref ref-type="bibr" rid="CR22">22</xref></sup>. For example, it has been reported in typical developing populations that increasing brain 5-HT with SSRIs can improve performance of a response inhibition task<sup><xref ref-type="bibr" rid="CR23">23</xref></sup>. Studies of sustained attention have also implicated 5-HT—possibly through its dampening effect on noradrenaline, dopamine and acetylcholine, which all play a key role in maintaining high levels of vigilance<sup><xref ref-type="bibr" rid="CR24">24</xref>,<xref ref-type="bibr" rid="CR25">25</xref></sup>. This is in line with evidence that both single and repeated dosages of SSRIs impair performance during sustained attention tasks in neurotypical populations<sup><xref ref-type="bibr" rid="CR22">22</xref>,<xref ref-type="bibr" rid="CR25">25</xref>–<xref ref-type="bibr" rid="CR27">27</xref></sup>.</p>
<p id="Par4">The serotonergic system is crucial to brain development in embryonic life<sup><xref ref-type="bibr" rid="CR28">28</xref></sup> and is also implicated in the pathophysiology of ASD. For example, the serotonin (5-HT) transporter gene (SLC6A4) has been associated with ASD<sup><xref ref-type="bibr" rid="CR29">29</xref></sup>, hyperserotonemia is frequently reported in children and adults<sup><xref ref-type="bibr" rid="CR30">30</xref></sup> and a decrease in density of 5-HT receptors<sup><xref ref-type="bibr" rid="CR31">31</xref></sup> and the 5-HT transporter<sup><xref ref-type="bibr" rid="CR32">32</xref></sup> has been observed in adults with ASD. In addition, we previously demonstrated that, in ASD boys, abnormalities in the activation of prefrontal regions during EF tasks (of motor inhibition, cognitive flexibility and working memory) were ‘normalised’ after a single dose of fluoxetine<sup><xref ref-type="bibr" rid="CR18">18</xref>,<xref ref-type="bibr" rid="CR33">33</xref>,<xref ref-type="bibr" rid="CR34">34</xref></sup>. However, to date no one has investigated the effect of an SSRI on EF networks in adults with ASD. In addition, no one has tested whether shifting of brain activation after SSRI administration is related to biological serotonergic markers, including peripheral 5-HT levels. If successful, this may help provide a rationale for further testing to determine if modulation of brain function is maintained by longer-term treatment.</p>
<p id="Par5">Therefore, we tested the effect of the SSRI citalopram on two EF networks (of response inhibition and sustained attention) in adults with ASD using pharmacological functional Magnetic Resonance Imaging (fMRI). Based on our previous work<sup><xref ref-type="bibr" rid="CR18">18</xref>,<xref ref-type="bibr" rid="CR33">33</xref>,<xref ref-type="bibr" rid="CR34">34</xref></sup>, we hypothesised that citalopram would modulate abnormal brain activation during EF towards control levels. In addition, we related peripheral 5-HT levels to change in brain activation after citalopram administration. Our subsidiary hypothesis was that degree of responsivity to citalopram would be associated with increased peripheral 5-HT levels.</p>
</sec>
<sec id="Sec2" sec-type="materials|methods">
<title>Materials and methods</title>
<sec id="Sec3">
<title>Participants</title>
<p id="Par6">Nineteen male, right-handed adults with ASD and 19 typically developed (TD) control participants were included in the study (age: TD mean = 27, SD = 9, ASD mean = 30, SD = 11). Two TD and 2 ASD cases were excluded from the Go/No-Go task due to significant head movement. The sample size was chosen based on results from our prior experiments targeting 5-HT modulation using both acute tryptophan depletion<sup><xref ref-type="bibr" rid="CR35">35</xref>,<xref ref-type="bibr" rid="CR36">36</xref></sup>, which were successful in detecting group differences in BOLD response with sample sizes of <italic>n</italic> = 14. This implies an effects size (expressed in Cohen’s d) in excess of 1.2<sup><xref ref-type="bibr" rid="CR35">35</xref>,<xref ref-type="bibr" rid="CR36">36</xref></sup>. Exclusion criteria included medical disorders that could influence cognitive performance, major mental illnesses other than ASD, genetic disorders associated with ASD, alcohol or substance dependence or taking any medication affecting the serotonergic system (e.g. antidepressants, antipsychotics, benzodiazepines or mood stabilisers). ASD diagnosis was made by a consultant psychiatrists using ICD-10 research criteria<sup><xref ref-type="bibr" rid="CR1">1</xref></sup> and confirmed using the Autism Diagnostic Interview-Revised (ADI-R)<sup><xref ref-type="bibr" rid="CR37">37</xref></sup> (Communication: mean = 20, SD = 7, Social Interaction: mean = 16, SD = 7, Repetitive Behaviour: mean = 5, SD = 2) if an informant was available. Current autistic symptoms were measured by the Autism Diagnostic Observation Schedule (ADOS)<sup><xref ref-type="bibr" rid="CR38">38</xref></sup> (Communication: mean = 3, SD = 2, Social Interaction: mean = 6, SD = 2). Intelligence was measured by the Wechsler Abbreviated Scale of Intelligence test (WASI)<sup><xref ref-type="bibr" rid="CR39">39</xref></sup> (TD mean = 115, SD = 10, ASD mean = 113, SD = 14). All participants completed baseline self-reported questionnaires of autistic traits (Autism-Spectrum Quotient)<sup><xref ref-type="bibr" rid="CR40">40</xref></sup>, obsessionality (Obsessive-Compulsive Inventory-Revised)<sup><xref ref-type="bibr" rid="CR41">41</xref></sup>, and current symptoms of ADHD (Barkley Adult ADHD Rating Scale—IV)<sup><xref ref-type="bibr" rid="CR42">42</xref></sup>. A brief interview was conducted by a medical doctor to assess symptoms of anxiety and depression using The Hamilton Rating Scales for Depression<sup><xref ref-type="bibr" rid="CR43">43</xref></sup> and Anxiety<sup><xref ref-type="bibr" rid="CR44">44</xref></sup>. All participants gave written, informed consent after receiving a complete description of the study. The study was ethically approved by the Stanmore Ethics Committee.</p>
</sec>
<sec id="Sec4">
<title>Platelet rich plasma serotonin</title>
<p id="Par7">In order to assess the peripheral serotonergic status of each participant, 7 ml of blood was collected in an anticoagulated EDTA tube, on one occasion, prior to drug administration. One tube was centrifuged at 140 <italic>×</italic> <italic>g</italic> for 25 minutes at 4 °C within 20 min after venipuncture. Centrifugation usually yielded ~3–4 ml of supernatant (platelet-rich plasma, PRP). A 1 ml aliquot of PRP was transferred into a 1.5 ml Eppendorf tube, frozen immediately, and stored at −80 °C until performance of Enzyme-Linked Immunosorbent Assay (ELISA) analysis of plasma 5-HT levels.</p>
</sec>
<sec id="Sec5">
<title>Citalopram administration procedure</title>
<p id="Par8">For the fMRI scans participants were required to complete two scanning sessions: one after receiving a single dose of 20 mg of encapsulated citalopram and one after receiving a dose of encapsulated placebo (ascorbic acid), in a randomised, double-blind, crossover design. A list of blinding numbers were produced independently and passed directly to the pharmacy in the outpatient department of the Maudsley Hospital using a computerised random number generator and using a blocked randomisation which allowed us to analyse our data at several time points in the study. The pharmacy used these numbers to blind each dose (placebo; encapsulated ascorbic acid/medication; citalopram) as they are manufactured. Both subject and researcher(s) were blind to dosing during the study. The randomisation and encapsulation was conducted according to Good Medical Practice and in accordance with CONSORT &amp; SPIRIT guidelines. Each dose was given to the participant 3 h prior to scanning, as citalopram reaches its peak plasma level after approximately 3 h<sup><xref ref-type="bibr" rid="CR45">45</xref></sup>. There was a minimum of eight days between the scans to allow for complete washout of the drug (t½ = 36 h; washout = 5*t½ = 7.5 days). All participants received a screening by a medical doctor before and after the administration of both doses.</p>
</sec>
<sec id="Sec6">
<title>Visual analogue scale</title>
<p id="Par9">All participants administered self-reported visual analogue scale questionnaires prior to drug administration and after the fMRI-scan. Symptoms potentially associated with citalopram were measured, including palpitations, nausea, dizziness, attentiveness, anxiety and irritability.</p>
</sec>
<sec id="Sec7">
<title>Go/No-Go inhibition fMRI task</title>
<p id="Par10">In order to probe the brain’s response inhibition system, a Go/No-Go task was performed during each scanning session<sup><xref ref-type="bibr" rid="CR19">19</xref>,<xref ref-type="bibr" rid="CR46">46</xref></sup>. During this task, either a motor response on a button box to Go signals is required or the inhibition of this response to No-Go signals. Arrows pointing to either the left or right side appear on the screen. The subject has to press the left or right response button on a diamond-shaped keypad as response. Infrequently (12%), arrows pointing to the top (No-Go signals) appear. Subjects have to inhibit their motor response to these stimuli. In 12% of trials, slightly slanted arrows pointing left or right appear and subjects have to treat them the same way as Go signals. In order to control for the attentional oddball effect due to the low frequency occurrence of No-Go trials, No-Go trials were compared to successful oddball trials<sup><xref ref-type="bibr" rid="CR19">19</xref>,<xref ref-type="bibr" rid="CR46">46</xref></sup>.</p>
</sec>
<sec id="Sec8">
<title>Sustained attention fMRI task</title>
<p id="Par11">In order to probe the brain’s sustained attention network system, the sustained attention task was performed during each scanning session<sup><xref ref-type="bibr" rid="CR16">16</xref>,<xref ref-type="bibr" rid="CR20">20</xref>,<xref ref-type="bibr" rid="CR47">47</xref></sup>. Subjects need to respond via a right hand button response as quickly as possible, and within 1 s, to the appearance of a visual timer counting up in milliseconds. When they press the button to the counter the counter will show their reaction time as it counts milliseconds. They are instructed to press as soon as they see the counter. The visual stimuli appear either after short, predictable consecutive delays of 0.5 s (260 stimuli in total), in series of 3–5 consecutive stimuli or after unpredictable time delays of 2, 5 or 8 s (20 each), which are pseudo-randomly interspersed into the blocks of 3–5 delays of 0.5 s. The long, infrequent, unpredictable delays place a higher load on sustained attention, as subjects have to wait for them to occur and they do not know the exact time of when they will occur (2, 5 or 8 s) whereas the short, predictable 0.5 s delays which appear in a row are typically anticipated. Participants learn to estimate the 0.5 s and know that there will be several stimuli appearing in a row<sup><xref ref-type="bibr" rid="CR48">48</xref></sup>, placing a higher demand on sensorimotor synchronisation<sup><xref ref-type="bibr" rid="CR20">20</xref></sup>. Activation to the longest delay (8 s) that placed the highest load on sustained attention, and showed most activation, was compared to brain activation during the short delays (0.5 s) (Supplementary Table <xref ref-type="media" rid="MOESM1">1</xref>).</p>
<p id="Par12">We have shown consistently with this task that sustained attention networks are activated during the long delays relative to the short delays and that, with longer delays, there is progressively increasing activation from 2 s to 8 s<sup><xref ref-type="bibr" rid="CR16">16</xref>,<xref ref-type="bibr" rid="CR20">20</xref>,<xref ref-type="bibr" rid="CR47">47</xref></sup>.</p>
</sec>
<sec id="Sec9">
<title>Characteristics and performance statistical analysis</title>
<p id="Par13">Statistical tests were performed using SPSS software (v23.0). <italic>T</italic>-tests were used to compare baseline characteristics between groups and multivariate analysis of variance (MANOVA) to determine any differences in performance and visual analogue scale outcome measures between group and drug conditions. Analysis of variance (ANOVA) was used to compare largest displacement in head movement between group and drug conditions.</p>
<p id="Par14">For the Go/No-Go task the performance measures include: probability of inhibition (main inhibitory measure), mean reaction time to the Go signal (motor execution measure) and mean reaction time to the oddball signal. For the sustained attention task the performance measures include: coefficient of variation (variation in reaction time during performance of the task adjusted for reaction time, i.e. standard deviation of reaction time divided by reaction time), mean reaction time, premature responses and omission errors.</p>
</sec>
<sec id="Sec10">
<title>fMRI image acquisition</title>
<p id="Par15">All participants were scanned on a 3-Tesla General Electric Signa HD x Twinspeed scanner (Milwaukee, Wisc.), fitted with a quadrature birdcage head coil. For the fMRI, we acquired 260 (Go/No-Go task) and 480 (sustained attention task) T2*-weighted volumes on 37 (Go/No-Go task) and 31 (sustained attention task) non-adjacent planes parallel to the anterior-posterior commissure (TE = 30 ms, TR = 1.8 s (Go/No-Go task); 1.5 s (sustained attention task), flip angle = 73° (Go/No-Go task); 68° (sustained attention task), slice thickness = 3.0 mm, in-plane voxel-size = 3.75 mm<sup>2</sup>, slice gap = 0.7 mm (Go/No-Go task); 1.4 mm (sustained attention task); matrix size = 64 × 64 voxels). Also, a high resolution gradient echo structural scan, on which activation maps were superimposed, was sagitally acquired to be used during normalisation of the fMRI data into Talairach space. (TR = 3 s, TE = 30 ms, 43 slices, flip angle = 90°, slice gap = 0.3 mm, slice thickness = 3.0 mm, matrix size = 128 × 128 voxels).</p>
</sec>
<sec id="Sec11">
<title>fMRI image analysis</title>
<p id="Par16">The fMRI data was analysed using XBAM (version 4) software developed at the Institute of Psychiatry, Psychology and Neuroscience<sup><xref ref-type="bibr" rid="CR49">49</xref></sup>. This method is decribed in brief in this section and in more detail in the supplementary material section. This non-parametric approach minimises assumptions involved in image processing and has been previously described<sup><xref ref-type="bibr" rid="CR36">36</xref></sup>. Within each run, every volume was realigned to the mean of all the images in the run and then smoothed using a Gaussian filter (full-width at half-maximum 8.8 mm). Using a wavelet-based resampling method for functional MRI data, a time series analysis was conducted on each individual subject, in order to compute a sum of squares (SSQ) ratio reflecting the BOLD effect. SSQ ratio maps were transformed into standard stereotactic space<sup><xref ref-type="bibr" rid="CR50">50</xref></sup> using a two-stage warping procedure<sup><xref ref-type="bibr" rid="CR49">49</xref></sup>. First, an average image intensity map for each individual was computed. We then determined the transformations required to map this image to the structural scan for each individual and then from ‘structural space’ to the Talairach template by maximising the correlation between the images at each stage. The SSQ ratios were then transformed into Talairach space using these same transformations. Group brain activation maps were computed for each drug condition with hypothesis testing performed at both the voxel and the cluster level. Using data-driven, permutation-based methods, with minimal distributional assumptions, we performed time series analyses for group maps and inter-group random permutation for within/between-group ANOVAs to compute the distribution of the SSQ ratio under the relevant null distribution hypothesis. Thresholding to the required level of significance was then performed using a two-stage process: first at a voxel-wise <italic>p</italic>-value of 0.05, followed by grouping the supra-threshold voxels into 3D clusters and testing their significance against a null distribution of clusters occurring by chance in the permuted data. A group brain activation map was produced for each group (TD, ASD) and medication (placebo, citalopram) status. We conducted all ANOVA analyses with <italic>p</italic> &lt; 0.05 for voxel level and with <italic>p</italic> &lt; 0.02 at cluster level. This resulted in less than one false positive cluster per map for the sustained attention task and three potentially false positive clusters for the Go/No-Go task.</p>
</sec>
<sec id="Sec12">
<title>Between group analysis of variance</title>
<p id="Par17">A main effect of group analysis was conducted for the placebo condition for each task. To investigate whether brain activation differences in the ASD group relative to the control group under placebo changed after citalopram dose in ASD, a main effect of group analysis was conducted in regions showing a main effect of group under placebo, but now comparing the control group on placebo with the ASD group on citalopram, to test for potential ‘normalisation’ effects. Furthermore, a within ASD effect of drug analysis was conducted, in regions showing a main effect of group, to investigate whether the degree of change in activation in ASD following citalopram was significant (‘normalised’).</p>
</sec>
<sec id="Sec13">
<title>Group x medication interaction analysis of variance</title>
<p id="Par18">A two-group (TD, ASD) by two-drug status (placebo, citalopram) factorial repeated-measures ANOVA was conducted for each task. In the groupxdrug status interactions the effect on the BOLD response in brain regions is different in each group depending on drug status. The cluster-level threshold was adjusted to <italic>p</italic> &lt; 0.02, resulting in less than one false-positive cluster per map.</p>
</sec>
<sec id="Sec14">
<title>Correlations between symptomatology, serotonin and change in functional activations</title>
<p id="Par19">Pearson’s correlations were conducted in XBAM to investigate any associations between core symptoms (measured by the ADI-R and ADOS), associated symptoms of ADHD, anxiety, depression and obsessionality (measured by the BAARS-IV, HAM-A, HAM-D and OCI-R), PRP 5-HT levels and difference in BOLD response between groups under the placebo condition or change between citalopram and placebo conditions (citalopram–placebo), in regions showing a main effect of group during placebo, during both tasks. The sum of square ratio was extracted for each cluster showing a correlation and plotted versus symptomatology or PRP 5-HT levels. A False Discovery Rate analysis was conducted to correct for multiple comparisons.</p>
</sec>
</sec>
<sec id="Sec15" sec-type="results">
<title>Results</title>
<sec id="Sec16">
<title>Baseline characteristics</title>
<p id="Par20">The groups did not significantly differ in age and IQ. As expected, control subjects scored significantly lower on baseline autistic traits and symptoms of anxiety, obsessionality, depression, inattention (childhood) and hyperactivity (currently and in childhood). There was no significant difference between groups in inattention scores currently (Table <xref ref-type="table" rid="Tab1">1</xref>).<table-wrap id="Tab1"><label>Table 1</label><caption><p>Subjects characteristics</p></caption><table frame="hsides" rules="groups"><thead><tr><th></th><th>TD (<italic>n</italic> = 19<sup>a</sup>)</th><th>ASD (<italic>n</italic> = 19<sup>a</sup>)</th><th><italic>t-</italic>test <italic>p</italic>-value</th></tr></thead><tbody><tr><td>Age</td><td>27 ± 9 (19–52)</td><td>30 ± 11 (19–50)</td><td>0.3</td></tr><tr><td>IQ</td><td>115 ± 10 (88–130)</td><td>113 ± 14 (79–139)</td><td>0.7</td></tr><tr><td>ADOS–Communication</td><td>–</td><td>3 ± 2</td><td></td></tr><tr><td>ADOS–Social interaction</td><td>–</td><td>6 ± 2</td><td></td></tr><tr><td>ADI-R–Communication</td><td>–</td><td>17 ± 9</td><td></td></tr><tr><td>ADI-R–Social interaction</td><td>–</td><td>14 ± 8</td><td></td></tr><tr><td>ADI-R–Repetitive behaviour</td><td>–</td><td>5 ± 2</td><td></td></tr><tr><td>AQ</td><td>12 ± 7</td><td>31 ± 11</td><td>&lt;0.001***</td></tr><tr><td>HAM-D</td><td>2 ± 3</td><td>6 ± 4</td><td>0.001**</td></tr><tr><td>HAM-A</td><td>3 ± 4</td><td>8 ± 6</td><td>0.003**</td></tr><tr><td>OCI-R</td><td>8 ± 9</td><td>23 ± 13</td><td>&lt;0.001***</td></tr><tr><td>GAD-7</td><td>3 ± 3</td><td>7 ± 5</td><td>0.01*</td></tr><tr><td>Barkley inattention childhood self</td><td>0.7 ± 1.2</td><td>3.3 ± 3.0</td><td>0.002**</td></tr><tr><td>Barkley hyperactivity childhood self</td><td>1.1 ± 1.9</td><td>3.7 ± 2.9</td><td>0.004**</td></tr><tr><td>Barkley inattention currently self</td><td>0.7 ± 1.5</td><td>1.4 ± 1.8</td><td>0.2</td></tr><tr><td>Barkley hyperactivity currently self</td><td>0.4 ± 0.8</td><td>1.2 ± 1.3</td><td>0.004**</td></tr></tbody></table><table-wrap-foot><p>Data in table is shown as mean ± standard deviation (range) (<italic>n</italic> = number of participants)</p><p><italic>TD</italic> typically developed controls, <italic>ASD</italic> individuals with autism spectrum disorder, <italic>ADOS</italic> Autism diagnostic observation scale, <italic>ADI-R</italic> Autism diagnostic interview-revised, <italic>AQ</italic> Autism quotient, <italic>HAM-D</italic> Hamilton Depression Rating Scale, <italic>HAM-A</italic> Hamilton Anxiety Rating Scale, <italic>OCI-R</italic> obsessive-compulsive inventory revised</p><p>Between group <italic>t</italic>-test: * = <italic>p</italic> &lt; 0.05; ** = <italic>p</italic> &lt; 0.01; *** = <italic>p</italic> &lt; 0.001</p><p><sup>a</sup><italic>n</italic> = 19 for Sustained Attention task and <italic>n</italic> = 17 for Go/No-Go task, which did not significantly affect between-group differences in baseline characteristics, platelet rich plasma serotonin (PRP 5-HT) levels or visual analogue scale measures</p></table-wrap-foot></table-wrap></p>
</sec>
<sec id="Sec17">
<title>Platelet rich plasma serotonin levels</title>
<p id="Par21">The data was normally distributed for each group, as assessed by the Shapiro-Wilk test (<italic>p</italic> &gt; 0.05). No significant differences were observed between groups in mean PRP 5-HT levels (TD mean = 324.1 μg/l, SD = 220.2, ASD mean = 316.1 μg/l, SD = 168.3; <italic>t</italic>(36) = 0.11, <italic>p</italic> <italic>=</italic> 0.91).</p>
</sec>
<sec id="Sec18">
<title>Performance</title>
<sec id="Sec19">
<title>Go/No-Go task</title>
<p id="Par22">Multivariate analysis of variance revealed no significant between-group or within-group differences for the probability of inhibition or mean reaction time to the Go or oddball stimuli (Supplementary Table <xref ref-type="media" rid="MOESM1">2</xref>).</p>
</sec>
<sec id="Sec20">
<title>Sustained attention task</title>
<p id="Par23">Multivariate analysis of variance revealed significant differences between TD and ASD during both the placebo and citalopram conditions on mean reaction time and coefficient of variation for the 0.5 and 8 s delays. Mean reaction time was slower and coefficient of variation higher in ASD compared to controls. For omission errors there was a significant group difference during the placebo condition for the 0.5 s delay and for premature responses, there were significant group differences during both placebo and citalopram conditions for the 0.5 s delay, with ASD showing more omission errors and premature responses. There were no significant within group differences in performance outcome following citalopram in both groups. However, when comparing control subjects during placebo with ASD cases during citalopram the group difference of coefficient of variation for the 8 s delay condition was no longer significant (Supplementary Table <xref ref-type="media" rid="MOESM1">3</xref>).</p>
</sec>
<sec id="Sec21">
<title>Visual analogue scales</title>
<p id="Par24">Despite baseline group differences in associated symptomatology (Table <xref ref-type="table" rid="Tab1">1</xref>), multivariate analysis of variance showed no significant difference after placebo or citalopram intake in both groups on subjective reports of physical and psychological symptoms, including palpitations, nausea, dizziness, anxiety, depression or irritability (Supplementary Table <xref ref-type="media" rid="MOESM1">4</xref>).</p>
</sec>
<sec id="Sec22">
<title>Movement</title>
<sec id="FPar1">
<title>Go/No-Go task</title>
<p id="Par25">For largest head displacement in three-dimensional space there was no significant effect of group (<italic>F</italic>(1, 64) = 1.13; <italic>p</italic> = 0.29), drug (<italic>F</italic>(1, 64) = 2.56; <italic>p</italic> = 0.11) or group × drug interaction (<italic>F</italic>(1, 64) = 0.02; <italic>p</italic> = 0.89) (Supplementary Table <xref ref-type="media" rid="MOESM1">5</xref>).</p>
</sec>
<sec id="FPar2">
<title>Sustained attention task</title>
<p id="Par26">For largest head displacement in three-dimensional space there was no significant effect of group (<italic>F</italic>(1, 72) = 2.3; <italic>p</italic> = 0.14), drug (<italic>F</italic>(1, 72) = 1.07; <italic>p</italic> = 0.30) or group × drug interaction (<italic>F</italic>(1, 72) = 0.01; <italic>p</italic> = 0.92) (Supplementary Table <xref ref-type="media" rid="MOESM1">5</xref>).</p>
</sec>
<sec id="FPar3">
<title>Within group brain activations</title>
<p id="Par27">The group activation maps for each group (TD, ASD) and medication (placebo, citalopram) status revealed significant activation during successful inhibition (No-Go &gt; Oddball) in response inhibition regions including inferior, superior and middle frontal, and pre- and postcentral cortex and cerebellum. During sustained attention significant activation was observed in superior and middle frontal, superior and middle temporal, occipital and pre- and postcentral cortices and cerebellum (Supplementary Tables <xref ref-type="media" rid="MOESM1">6</xref>–<xref ref-type="media" rid="MOESM1">13</xref>, Supplementary Figs. <xref ref-type="media" rid="MOESM1">1</xref> and <xref ref-type="media" rid="MOESM1">2</xref>).</p>
</sec>
</sec>
</sec>
<sec id="Sec23">
<title>Group differences in brain activation during placebo and citalopram</title>
<sec id="Sec24">
<title>Go/No-Go task</title>
<p id="Par28">During placebo, subjects with ASD relative to controls showed a decrease in activation in right postcentral cortex (<italic>p</italic> = 0.009, cluster size = 144 voxels). An increase in activation in ASD compared to controls was observed in left inferior frontal cortex/left insula (<italic>p</italic> = 0.02, cluster size = 95 voxels), right precentral cortex (<italic>p</italic> = 0.01, cluster size = 111 voxels), right cerebellum (<italic>p</italic> = 0.02, cluster size = 81 voxels) and right occipital cortex (<italic>p</italic> = 0.01, cluster size = 114 voxels) (Fig. <xref ref-type="fig" rid="Fig1">1a</xref>, Table <xref ref-type="table" rid="Tab2">2</xref>).<fig id="Fig1"><label>Fig. 1</label><caption><p>Brain activation map showing abnormally activated regions during response inhibition and sustained attention in ASD that were ‘normalised’ by citalopram; <italic>p</italic> &lt; 0.02 at cluster level. Location of BOLD signal changes between groups. Red: TD &lt; ASD; Blue: TD &gt; ASD. Numeric label = z Talairach coordinate. Right hemisphere of brain is on the right side of the image. Abbreviations: BOLD, blood-oxygen-level dependent; TD, Typically Developed Controls; ASD, Individuals with Autism Spectrum Disorder</p></caption><graphic id="d29e1184" xlink:href="41398_2019_641_Fig1_HTML"></graphic></fig><table-wrap id="Tab2"><label>Table 2</label><caption><p>Anatomical location and statistics for BOLD activation</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Region</th><th><italic>X</italic></th><th><italic>Y</italic></th><th><italic>Z</italic></th><th>Cluster <italic>p</italic>-value</th><th>Cluster size</th></tr></thead><tbody><tr><td colspan="6"><italic>GO/NO-GO task</italic></td></tr><tr><td colspan="6"><italic>TD placebo vs ASD placebo</italic></td></tr><tr><td colspan="6"><italic>TD&gt;ASD (blue)</italic></td></tr><tr><td> Right postcentral cortex</td><td>58</td><td>−19</td><td>33</td><td>0.009</td><td>144</td></tr><tr><td colspan="6"><italic>TD&lt;ASD (red)</italic></td></tr><tr><td> Right cerebellum</td><td>29</td><td>−67</td><td>−40</td><td>0.02</td><td>81</td></tr><tr><td> Right occipital cortex</td><td>11</td><td>−96</td><td>−7</td><td>0.01</td><td>114</td></tr><tr><td> Left inferior frontal cortex/left insula</td><td>−40</td><td>19</td><td>13</td><td>0.02</td><td>95</td></tr><tr><td> Right precentral cortex</td><td>43</td><td>−7</td><td>50</td><td>0.01</td><td>111</td></tr><tr><td colspan="6"><italic>TD placebo vs ASD citalopram</italic></td></tr><tr><td colspan="6"><italic>TD&gt;ASD (blue)</italic></td></tr><tr><td> Right postcentral cortex</td><td>43</td><td>−22</td><td>33</td><td>0.005</td><td>25</td></tr><tr><td colspan="6">Interaction of drug status (placebo, citalopram) by group (TD, ASD)</td></tr><tr><td> Left Cerebellum, Posterior Lobe (Crus I/II)</td><td>−22</td><td>−81</td><td>−33</td><td>0.01</td><td>132</td></tr><tr><td colspan="6"><italic>SUSTAINED ATTENTION task</italic></td></tr><tr><td colspan="6"><italic>TD placebo vs ASD placebo</italic></td></tr><tr><td colspan="6"><italic>TD&gt;ASD (blue)</italic></td></tr><tr><td>Right middle temporal cortex</td><td>61</td><td>−7</td><td>−7</td><td>0.02</td><td>212</td></tr><tr><td>Right cuneus</td><td>14</td><td>−93</td><td>3</td><td>0.0008</td><td>1082</td></tr><tr><td>Left precuneus</td><td>−4</td><td>−63</td><td>46</td><td>0.009</td><td>747</td></tr><tr><td colspan="6"><italic>TD placebo vs ASD citalopram</italic></td></tr><tr><td colspan="6"><italic>TD&gt;ASD (blue)</italic></td></tr><tr><td>Right Cuneus</td><td>14</td><td>−93</td><td>3</td><td>0.03</td><td>129</td></tr></tbody></table><table-wrap-foot><p>x, y, z = Peak Talairach coordinates</p><p><italic>BOLD</italic> blood-oxygen-level dependent, <italic>TD</italic> typically developed controls, <italic>ASD</italic> individuals with Autism spectrum disorder</p></table-wrap-foot></table-wrap></p>
<p id="Par29">In order to test potential ‘normalisation’ effects, subjects with ASD during citalopram were compared to controls during placebo focusing on regions where between-group differences under placebo were observed. Nearly all between group differences were no longer observed, leaving only one small decrease in activation in subjects with ASD compared to controls in right postcentral cortex (<italic>p</italic> = 0.005, cluster size = 25 voxels) (Fig. <xref ref-type="fig" rid="Fig1">1b</xref>, Table <xref ref-type="table" rid="Tab2">2</xref>). Subsequently, a within ASD analysis was conducted to investigate the effect of drug in those regions specifically. Only the decrease in overactivation of left insula significantly ‘normalised’ (<italic>p</italic> = 0.04, see Fig. <xref ref-type="fig" rid="Fig2">2</xref>).<fig id="Fig2"><label>Fig. 2</label><caption><p>Significant decrease (‘normalisation’) in brain activation during response inhibition in left inferior frontal cortex within ASD following citalopram administration. Abbreviations: SSQ, sum of squares (statistical measure of BOLD response); * = <italic>p</italic> &lt; 0.05</p></caption><graphic id="d29e1538" xlink:href="41398_2019_641_Fig2_HTML"></graphic></fig></p>
</sec>
<sec id="Sec25">
<title>Sustained attention task</title>
<p id="Par30">During placebo, subjects with ASD relative to controls showed a decrease in activation in right middle temporal cortex (<italic>p</italic> = 0.02, cluster size = 212 voxels), right cuneus (<italic>p</italic> = 0.001, cluster size = 1082 voxels) and left precuneus (<italic>p</italic> = 0.009, cluster size = 747 voxels) (Fig. <xref ref-type="fig" rid="Fig1">1c</xref>, Table <xref ref-type="table" rid="Tab2">2</xref>).</p>
<p id="Par31">In order to test potential ‘normalisation’ effects, subjects with ASD during citalopram were compared to controls during placebo focusing on regions where between-group differences under placebo were observed. Nearly all between group differences were no longer observed, leaving only one small decrease in activation in subjects with ASD compared to controls in right cuneus (<italic>p</italic> = 0.03, cluster size = 129 voxels) (Fig. <xref ref-type="fig" rid="Fig1">1d</xref>, Table <xref ref-type="table" rid="Tab2">2</xref>). Subsequently, a within ASD analysis was conducted to investigate the effect of drug in those regions specifically. Non of the regions ‘normalised’ significantly.</p>
</sec>
<sec id="Sec26">
<title>Group by drug interaction effects</title>
<sec id="FPar4">
<title>Go/No-Go task</title>
<p id="Par32">There was a significant interaction effect of BOLD signal response between drug status (placebo, citalopram) and group (TD, ASD) in left cerebellum (posterior lobe, crus I/II; <italic>p</italic> = 0.01 cluster size = 132 voxels). In this region citalopram decreased brain activation in the control group but increased brain activation in ASD (Fig. <xref ref-type="fig" rid="Fig3">3</xref> and Table <xref ref-type="table" rid="Tab2">2</xref>).<fig id="Fig3"><label>Fig. 3</label><caption><p>Interaction of drug status (placebo, citalopram) by group (TD, ASD) during response inhibition; <italic>p</italic> &lt; 0.02 at cluster level. Location of BOLD signal for ANOVA interaction. Numeric label = z Talairach coordinate. Box plots: Mean BOLD signal extracted from each interaction cluster. Right hemisphere of brain is on the right side of the image. Abbreviations: SSQ, sum of squares fMRI statistic; BOLD, blood-oxygen-level dependent; TD, Typically Developed Controls; ASD, Individuals with Autism Spectrum Disorder</p></caption><graphic id="d29e1598" xlink:href="41398_2019_641_Fig3_HTML"></graphic></fig></p>
</sec>
<sec id="FPar5">
<title>Sustained attention task</title>
<p id="Par33">There were no significant interaction effects of BOLD signal response between drug status (placebo, citalopram) and group (TD, ASD).</p>
</sec>
</sec>
</sec>
<sec id="Sec27">
<title>Correlations between functional activations and symptomatology and peripheral 5-HT within ASD</title>
<sec id="Sec28">
<title>Go/No-Go task</title>
<p id="Par34">Within ASD, baseline PRP 5-HT levels correlated positively with BOLD signal under placebo condition in the left insula (<italic>r</italic> = 0.81, <italic>p</italic> &lt; 0.001, cluster size = 23; at baseline increased activation in ASD compared to TD; extending from left inferior frontal cortex). Also, the degree of BOLD signal change between citalopram and placebo correlated negatively with PRP 5-HT levels in left insula (<italic>r</italic> = −0.8, <italic>p</italic> &lt; 0.0001, cluster size = 42 voxels; at baseline increased activation in ASD compared to TD; extending from left inferior frontal cortex) and positively in the right postcentral cortex (<italic>r</italic> = 0.8, <italic>p</italic> &lt; 0.0001, cluster size = 52 voxels; at baseline decreased activation in ASD compared to TD) (Supplementary Fig. <xref ref-type="media" rid="MOESM1">3</xref>). Hence, the higher the individual’s PRP 5-HT levels were at baseline, the more likely their brain activation in left insula and right postcentral cortex would ‘normalise’ after citalopram.</p>
</sec>
<sec id="Sec29">
<title>Sustained attention task</title>
<p id="Par35">Within ASD, ADOS communication scores correlated negatively with BOLD signal under placebo condition in right cuneus (<italic>r</italic> = −0.59, <italic>p</italic> = 0.01, cluster size = 201; at baseline decreased activation in ASD compared to TD). Furthermore, the degree of BOLD signal change between citalopram and placebo correlated positively with severity of current hyperactivity symptoms in the right middle temporal cortex (<italic>r</italic> = 0.7, <italic>p</italic> = 0.001, cluster size = 71 voxels; at baseline decreased activation in ASD compared to TD) and with severity of current inattention symptoms in the right postcentral cortex (<italic>r</italic> = 0.7, <italic>p</italic> = 0.001, cluster size = 84 voxels; at baseline decreased activation in ASD compared to TD) (Supplementary Fig. <xref ref-type="media" rid="MOESM1">3</xref>). Hence, the more severe an individual’s hyperactivity or inattention scores were at baseline, the more likely their brain activation would ‘normalise’ after citalopram.</p>
<p id="Par36">No correlations between functional activations and PRP 5-HT levels or symptoms were observed in the TD group.</p>
</sec>
</sec>
</sec>
<sec id="Sec30" sec-type="discussion">
<title>Discussion</title>
<p id="Par37">To our knowledge, this is the first fMRI study to examine the effect of citalopram on brain activation during EF in adults with ASD. We observed abnormal brain activation in adults with ASD compared to controls during successful inhibitory control in left inferior frontal, right precentral and postcentral cortices, and right cerebellum. During sustained attention, we observed reduced brain activation in ASD compared to controls in the right middle temporal cortex, right cuneus and left precuneus. Following citalopram dosing, these atypical brain activations during both tasks were mostly ‘abolished’ and during response inhibition ‘normalised’ in left inferior frontal cortex. Further studies are needed to determine if ‘normalisation’ of brain response during EF tasks is maintained by longer term citalopram treatment, and associated with treatment response.</p>
<p id="Par38">The observed group differences under placebo condition in brain activation during the EF tasks are partially in line with previous work. For instance, we previously reported abnormal brain activation during response inhibition in children with ASD<sup><xref ref-type="bibr" rid="CR18">18</xref></sup> and adults with Asperger’s syndrome<sup><xref ref-type="bibr" rid="CR19">19</xref></sup>. Both studies reported increased activation of left inferior frontal cortex, a region that is critical for successful response inhibition, specifically motor responses<sup><xref ref-type="bibr" rid="CR51">51</xref></sup>. Bilateral inferior frontal cortex has been associated with inhibitory control in fMRI<sup><xref ref-type="bibr" rid="CR52">52</xref>–<xref ref-type="bibr" rid="CR54">54</xref></sup>, lesion<sup><xref ref-type="bibr" rid="CR55">55</xref></sup> and transcranial magnetic stimulation (TMS) studies<sup><xref ref-type="bibr" rid="CR56">56</xref>,<xref ref-type="bibr" rid="CR57">57</xref></sup>. However, bilateral inferior frontal cortex has also been associated with the broader role in target detection or oddball attention processes that may expedite response inhibition<sup><xref ref-type="bibr" rid="CR58">58</xref>–<xref ref-type="bibr" rid="CR60">60</xref></sup>. Likewise, the finding in the present study of decreased brain activation during sustained attention partially overlaps with our previous studies of the same task in ASD children<sup><xref ref-type="bibr" rid="CR20">20</xref></sup> and a mixture of children and adults<sup><xref ref-type="bibr" rid="CR16">16</xref></sup>. In these studies we reported decreased brain activity in prefrontal, parietal, temporal, striato-thalamic and cerebellar regions. Thus, our findings of abnormal brain activation during both tasks support the suggestion that individuals with ASD have abnormalities in brain activation during EF.</p>
<p id="Par39">Our finding of ‘normalisation’ in brain function differences during response inhibition after citalopram is also in line with a previous fMRI investigation of an acute dose of fluoxetine in boys with ASD<sup><xref ref-type="bibr" rid="CR18">18</xref></sup>. Taken together these studies suggest that SSRIs can modulate abnormal brain activation in both children and adults with ASD. In addition, within ASD individuals we observed a strong association between PRP 5-HT levels and the degree of ‘normalisation’ in left inferior frontal cortex and right postcentral cortex. In contrast, however, no associations were observed within the control group. This suggests that baseline PRP 5-HT levels may underpin brain functional response to citalopram, but specifically in ASD. However, as we did not include a control group with a mood or anxiety disorder, we cannot rule out the possibility that this effect may also be present in such populations.</p>
<p id="Par40">The ‘abolition’ effect of citalopram on brain function abnormalities in sustained attention networks in ASD is a novel finding. Also, the degree of ‘abolition’ after citalopram in right middle temporal and postcentral cortex correlated with hyperactivity and inattention symptoms, respectively. In addition, impaired task performance in ASD compared to controls was no longer significant after citalopram administration (for coefficient of variation). Moreover, we observed a significant increase in a self-reported measure of inattentiveness after citalopram in the control group, but not in ASD. This suggests that citalopram improves both attention performance and its underlying neurofunctional networks in ASD. This could potentially transfer into clinical improvement of inattention symptoms, which are also present in frequent comorbid psychiatric conditions such as ADHD<sup><xref ref-type="bibr" rid="CR61">61</xref></sup> and depression<sup><xref ref-type="bibr" rid="CR62">62</xref>,<xref ref-type="bibr" rid="CR63">63</xref></sup>.</p>
<p id="Par41">Our interaction analysis during response inhibition revealed that in the left cerebellum (posterior lobe crus I/II), a region that is involved in cognitive control<sup><xref ref-type="bibr" rid="CR64">64</xref>,<xref ref-type="bibr" rid="CR65">65</xref></sup> and connected to the frontal cortex<sup><xref ref-type="bibr" rid="CR66">66</xref></sup>, citalopram shifted brain activation in the opposite direction in ASD compared to controls - citalopram decreased brain activation in the control group, but increased brain activation in ASD. This “reversal” of brain activation may reflect structural cerebellar abnormalities as well as dysfunctions of frontal-cerebellar networks that have frequently been reported in ASD populations. For example, abnormalities in structural white matter connectivity both within the cerebellum as well as its cortical and mid-brain projections have been reported in ASD<sup><xref ref-type="bibr" rid="CR67">67</xref>,<xref ref-type="bibr" rid="CR68">68</xref></sup>. Functional connectivity studies support these findings, suggesting differences in connections between the cerebellum and both motor and non-motor regions of the cortex in ASD<sup><xref ref-type="bibr" rid="CR69">69</xref>,<xref ref-type="bibr" rid="CR70">70</xref></sup>. This suggests that the neuropharmacological impact of citalopram is different in ASD than in controls. Therefore, it is possible that results from treatment studies in typically developed populations cannot be directly translated to individuals with ASD. This stresses the need for pharmacological interventions, affecting the serotonergic system, to be tested specifically in ASD.</p>
<p id="Par42">Our study has a number of limitations. First, we only included high functioning adult males and therefore cannot generalise our findings to other groups including females, children or lower functioning individuals. Second, we only used a single dosage of citalopram and we therefore cannot comment on whether the ‘normalisation’ effects will be maintained by long-term treatments. Third, for the Go/No-Go task, we did not find any differences in performance measures. This, however, is in line with a previous study using the Go/No-Go task<sup><xref ref-type="bibr" rid="CR35">35</xref></sup> and possibly caused by our relatively small sample size, that may be underpowered for behavioural data. For example, a recent study using a much larger sample (201 ASD cases and 240 controls) employed an online Go/No-Go task and reported deficits in response inhibition that was associated with diagnosis and autistic traits<sup><xref ref-type="bibr" rid="CR15">15</xref></sup>. Nevertheless, our sample was large enough to detect brain activation differences, which have previously been reported to be more sensitive to drug effects than behaviour, including in fMRI studies of ASD<sup><xref ref-type="bibr" rid="CR34">34</xref>,<xref ref-type="bibr" rid="CR35">35</xref></sup>. Last, the <italic>p</italic>-value at cluster level was set at 0.02, which resulted in less than one false positive cluster per map for the sustained attention task but three potentially false positive clusters for the Go/No-Go task. Therefore, three of the reported regions may be false-positive clusters. However, we decided to include them as they overlap with regions previously reported to show abnormal activation in ASD population (e.g. increased activation in left inferior frontal cortex)<sup><xref ref-type="bibr" rid="CR18">18</xref>,<xref ref-type="bibr" rid="CR19">19</xref>,<xref ref-type="bibr" rid="CR35">35</xref></sup>.</p>
<p id="Par43">In conclusion, we report that, within individuals with ASD, citalopram can ‘normalise’ brain functional differences during EF, and these modulations are associated with PRP 5-HT levels. This suggests a potential utility of citalopram for targeting EF related problems (e.g. core symptoms) in ASD. Therefore, future trials should investigate whether this shift in brain activation after a single dosage of citalopram is maintained after prolonged treatment, and whether this is associated with treatment response. Additionally, further studies are required to determine whether long-term treatment outcome to SSRIs is associated with elevated 5-HT levels.</p>
</sec>
<sec sec-type="supplementary-material">
<title>Supplementary information</title>
<sec id="Sec31">
<p>
<supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="41398_2019_641_MOESM1_ESM.docx"><caption><p>Supplementary material</p></caption></media></supplementary-material>
</p>
</sec>
</sec>
</body>
<back>
<fn-group>
<fn>
<p><bold>Publisher’s note</bold> Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p>
</fn>
<fn>
<p>These authors contributed equally: Declan G. M. Murphy, Eileen M. Daly</p>
</fn>
</fn-group>
<sec>
<title>Supplementary information</title>
<p><bold>Supplementary Information</bold> accompanies this paper at (10.1038/s41398-019-0641-0).</p>
</sec>
<ack>
<title>Acknowledgements</title>
<p>We would like to thank all the volunteers for their participation. We acknowledge support from the Clinical Biochemistry Department at King’s College Hospital, the Maudsley Pharmacy Department and the Neurodevelopmental Clinic at the Maudsley Hospital. We acknowledge support from the National Institute for Health Research (NIHR) Biomedical Research Centre for Mental Health at South London and Maudsley NHS Foundation Trust and Institute of Psychiatry, Psychology and Neuroscience King’s College London. This article presents independent research funded by the National Institute for Health Research (NIHR). The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health. This study was funded by a grant (to Prof. D.G Murphy) from European Autism Interventions - A Multicentre Study for Developing New Medications (EU-AIMS) (receiving support from the Innovative Medicines Initiative Joint Undertaking under grant agreement 115300, which includes financial contributions from the EU Seventh Framework Programme [FP7/2007–2013] and from the European Federation of Pharmaceutical Industries and Associations), a grant from EU-AIMS-2-TRIALS (to Prof. D.G. Murphy), a grant (to Prof. D.G Murphy) from NIHR Mental Health Biomedical Research Centre Infrastructure Support for Pilot Studies and a grant (to Prof. D.G Murphy) from the Sackler Institute for Translational Neurodevelopment.</p>
</ack>
<notes notes-type="COI-statement">
<title>Conflict of interest</title>
<p id="Par44">Professor K. Rubia has received speaker’s honoraria from Shire and Medice and grants from Lilly and Shire. The other authors report no financial relationships with commercial interests.</p>
</notes>
<ref-list id="Bib1">
<title>References</title>
<ref id="CR1">
<label>1.</label>
<mixed-citation publication-type="other">WHO. <italic>The ICD-10 classification of mental and behavioural disorders: diagnostic criteria for research</italic>. (World Health Organizartion, Geneva, 1993)</mixed-citation>
</ref>
<ref id="CR2">
<label>2.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Murray</surname>
<given-names>ML</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Pharmacological treatments prescribed to people with autism spectrum disorder (ASD) in primary health care</article-title>
<source/>Psychopharmacol. (Berl.)
          <year>2014</year>
<volume>231</volume>
<fpage>1011</fpage>
<lpage>1021</lpage>
<pub-id pub-id-type="doi">10.1007/s00213-013-3140-7</pub-id>
</element-citation>
</ref>
<ref id="CR3">
<label>3.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hsia</surname>
<given-names>Y</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Psychopharmacological prescriptions for people with autism spectrum disorder (ASD): a multinational study</article-title>
<source/>Psychopharmacol. (Berl.)
          <year>2014</year>
<volume>231</volume>
<fpage>999</fpage>
<lpage>1009</lpage>
<pub-id pub-id-type="doi">10.1007/s00213-013-3263-x</pub-id>
</element-citation>
</ref>
<ref id="CR4">
<label>4.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Croen</surname>
<given-names>LA</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The health status of adults on the autism spectrum</article-title>
<source/>Autism
          <year>2015</year>
<volume>19</volume>
<fpage>814</fpage>
<lpage>823</lpage>
<pub-id pub-id-type="doi">10.1177/1362361315577517</pub-id>
<pub-id pub-id-type="pmid">25911091</pub-id>
</element-citation>
</ref>
<ref id="CR5">
<label>5.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lever</surname>
<given-names>AG</given-names>
</name>
<name>
<surname>Geurts</surname>
<given-names>HM</given-names>
</name>
</person-group>
<article-title>Psychiatric co-occurring symptoms and disorders in young, middle-aged, and older adults with autism spectrum disorder</article-title>
<source/>J. Autism Dev. Disord.
          <year>2016</year>
<volume>46</volume>
<fpage>1916</fpage>
<lpage>1930</lpage>
<pub-id pub-id-type="doi">10.1007/s10803-016-2722-8</pub-id>
<pub-id pub-id-type="pmid">26861713</pub-id>
</element-citation>
</ref>
<ref id="CR6">
<label>6.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Roy</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Prox-Vagedes</surname>
<given-names>V</given-names>
</name>
<name>
<surname>D Ohlmeier</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Dillo</surname>
<given-names>W</given-names>
</name>
</person-group>
<article-title>Beyond childhood: psychiatric comorbidities and social background of adults with Asperger syndrome</article-title>
<source/>Psychiatr. Danubina
          <year>2015</year>
<volume>27</volume>
<fpage>0</fpage>
<lpage>59</lpage>
</element-citation>
</ref>
<ref id="CR7">
<label>7.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Joshi</surname>
<given-names>G</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Psychiatric comorbidity and functioning in a clinically referred population of adults with autism spectrum disorders: a comparative study</article-title>
<source/>J. Autism Developmental Disord.
          <year>2013</year>
<volume>43</volume>
<fpage>1314</fpage>
<lpage>1325</lpage>
<pub-id pub-id-type="doi">10.1007/s10803-012-1679-5</pub-id>
</element-citation>
</ref>
<ref id="CR8">
<label>8.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hollander</surname>
<given-names>E</given-names>
</name>
<etal></etal>
</person-group>
<article-title>A double-blind placebo-controlled trial of fluoxetine for repetitive behaviors and global severity in adult autism spectrum disorders</article-title>
<source/>Am. J. psychiatry
          <year>2012</year>
<volume>169</volume>
<fpage>292</fpage>
<lpage>299</lpage>
<pub-id pub-id-type="doi">10.1176/appi.ajp.2011.10050764</pub-id>
<pub-id pub-id-type="pmid">22193531</pub-id>
</element-citation>
</ref>
<ref id="CR9">
<label>9.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Buchsbaum</surname>
<given-names>MS</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Effect of fluoxetine on regional cerebral metabolism in autistic spectrum disorders: a pilot study</article-title>
<source/>Int. J. Neuropsychopharmacol
          <year>2001</year>
<volume>4</volume>
<fpage>119</fpage>
<lpage>125</lpage>
<pub-id pub-id-type="doi">10.1017/S1461145701002280</pub-id>
<pub-id pub-id-type="pmid">11466160</pub-id>
</element-citation>
</ref>
<ref id="CR10">
<label>10.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>McDougle</surname>
<given-names>CJ</given-names>
</name>
<etal></etal>
</person-group>
<article-title>A double-blind, placebo-controlled study of fluvoxamine in adults with autistic disorder</article-title>
<source/>Arch. Gen. psychiatry
          <year>1996</year>
<volume>53</volume>
<fpage>1001</fpage>
<lpage>1008</lpage>
<pub-id pub-id-type="doi">10.1001/archpsyc.1996.01830110037005</pub-id>
<pub-id pub-id-type="pmid">8911223</pub-id>
</element-citation>
</ref>
<ref id="CR11">
<label>11.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Collier</surname>
<given-names>R</given-names>
</name>
</person-group>
<article-title>Rapidly rising clinical trial costs worry researchers</article-title>
<source/>CMAJ
          <year>2009</year>
<volume>180</volume>
<fpage>277</fpage>
<lpage>278</lpage>
<pub-id pub-id-type="doi">10.1503/cmaj.082041</pub-id>
<pub-id pub-id-type="pmid">19188619</pub-id>
</element-citation>
</ref>
<ref id="CR12">
<label>12.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Happe</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Ronald</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Plomin</surname>
<given-names>R</given-names>
</name>
</person-group>
<article-title>Time to give up on a single explanation for autism</article-title>
<source/>Nat. Neurosci.
          <year>2006</year>
<volume>9</volume>
<fpage>1218</fpage>
<lpage>1220</lpage>
<pub-id pub-id-type="doi">10.1038/nn1770</pub-id>
<pub-id pub-id-type="pmid">17001340</pub-id>
</element-citation>
</ref>
<ref id="CR13">
<label>13.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lopez</surname>
<given-names>BR</given-names>
</name>
<name>
<surname>Lincoln</surname>
<given-names>AJ</given-names>
</name>
<name>
<surname>Ozonoff</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Lai</surname>
<given-names>Z</given-names>
</name>
</person-group>
<article-title>Examining the relationship between executive functions and restricted, repetitive symptoms of Autistic Disorder</article-title>
<source/>J. Autism Dev. Disord.
          <year>2005</year>
<volume>35</volume>
<fpage>445</fpage>
<lpage>460</lpage>
<pub-id pub-id-type="doi">10.1007/s10803-005-5035-x</pub-id>
<pub-id pub-id-type="pmid">16134030</pub-id>
</element-citation>
</ref>
<ref id="CR14">
<label>14.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Diamond</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Executive functions</article-title>
<source/>Annu. Rev. Psychol.
          <year>2013</year>
<volume>64</volume>
<fpage>135</fpage>
<lpage>168</lpage>
<pub-id pub-id-type="doi">10.1146/annurev-psych-113011-143750</pub-id>
<pub-id pub-id-type="pmid">23020641</pub-id>
</element-citation>
</ref>
<ref id="CR15">
<label>15.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Uzefovsky</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Allison</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Smith</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Baron-Cohen</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Brief Report: the Go/No-Go task online: inhibitory control deficits in autism in a large sample</article-title>
<source/>J. Autism Dev. Disord.
          <year>2016</year>
<volume>46</volume>
<fpage>2774</fpage>
<lpage>2779</lpage>
<pub-id pub-id-type="doi">10.1007/s10803-016-2788-3</pub-id>
<pub-id pub-id-type="pmid">27103120</pub-id>
</element-citation>
</ref>
<ref id="CR16">
<label>16.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Murphy</surname>
<given-names>CM</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Abnormal functional activation and maturation of fronto-striato-temporal and cerebellar regions during sustained attention in autism spectrum disorder</article-title>
<source/>Am. J. Psychiat
          <year>2014</year>
<volume>171</volume>
<fpage>1107</fpage>
<lpage>1116</lpage>
<pub-id pub-id-type="doi">10.1176/appi.ajp.2014.12030352</pub-id>
<pub-id pub-id-type="pmid">24873905</pub-id>
</element-citation>
</ref>
<ref id="CR17">
<label>17.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Corbett</surname>
<given-names>BA</given-names>
</name>
<name>
<surname>Constantine</surname>
<given-names>LJ</given-names>
</name>
</person-group>
<article-title>Autism and attention deficit hyperactivity disorder: assessing attention and response control with the integrated visual and auditory continuous performance test</article-title>
<source/>Child neuropsychology: a J. Norm. Abnorm. Dev. Child. adolescence
          <year>2006</year>
<volume>12</volume>
<fpage>335</fpage>
<lpage>348</lpage>
<pub-id pub-id-type="doi">10.1080/09297040500350938</pub-id>
</element-citation>
</ref>
<ref id="CR18">
<label>18.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chantiluke</surname>
<given-names>K</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Inverse fluoxetine effects on inhibitory brain activation in non-comorbid boys with ADHD and with ASD</article-title>
<source/>Psychopharmacol. (Berl.)
          <year>2015</year>
<volume>232</volume>
<fpage>2071</fpage>
<lpage>2082</lpage>
<pub-id pub-id-type="doi">10.1007/s00213-014-3837-2</pub-id>
</element-citation>
</ref>
<ref id="CR19">
<label>19.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schmitz</surname>
<given-names>N</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Neural correlates of executive function in autistic spectrum disorders</article-title>
<source/>Biol. psychiatry
          <year>2006</year>
<volume>59</volume>
<fpage>7</fpage>
<lpage>16</lpage>
<pub-id pub-id-type="doi">10.1016/j.biopsych.2005.06.007</pub-id>
<pub-id pub-id-type="pmid">16140278</pub-id>
</element-citation>
</ref>
<ref id="CR20">
<label>20.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Christakou</surname>
<given-names>A</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Disorder-specific functional abnormalities during sustained attention in youth with Attention Deficit Hyperactivity Disorder (ADHD) and with autism</article-title>
<source/>Mol. psychiatry
          <year>2013</year>
<volume>18</volume>
<fpage>236</fpage>
<lpage>244</lpage>
<pub-id pub-id-type="doi">10.1038/mp.2011.185</pub-id>
<pub-id pub-id-type="pmid">22290121</pub-id>
</element-citation>
</ref>
<ref id="CR21">
<label>21.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Robbins</surname>
<given-names>TWC</given-names>
</name>
<name>
<surname>Christian</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Barry</surname>
<given-names>PM</given-names>
</name>
<name>
<surname>Role</surname>
<given-names>LJ</given-names>
</name>
</person-group>
<article-title>of Central serotonin in impulsivity and compulsivity: comparative studies in experimental animals and humans</article-title>
<source/>Handb. Behav. Neurosci. Elsevier.
          <year>2010</year>
<volume>21</volume>
<fpage>415</fpage>
<lpage>427</lpage>
<pub-id pub-id-type="doi">10.1016/S1569-7339(10)70093-X</pub-id>
</element-citation>
</ref>
<ref id="CR22">
<label>22.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Riedel</surname>
<given-names>WJ</given-names>
</name>
<name>
<surname>Eikmans</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Heldens</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Schmitt</surname>
<given-names>JA</given-names>
</name>
</person-group>
<article-title>Specific serotonergic reuptake inhibition impairs vigilance performance acutely and after subchronic treatment</article-title>
<source/>J. Psychopharmacol.
          <year>2005</year>
<volume>19</volume>
<fpage>12</fpage>
<lpage>20</lpage>
<pub-id pub-id-type="doi">10.1177/0269881105048887</pub-id>
<pub-id pub-id-type="pmid">15671124</pub-id>
</element-citation>
</ref>
<ref id="CR23">
<label>23.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Homberg</surname>
<given-names>JR</given-names>
</name>
</person-group>
<article-title>Serotonin and decision making processes</article-title>
<source/>Neurosci. Biobehav. Rev.
          <year>2012</year>
<volume>36</volume>
<fpage>218</fpage>
<lpage>236</lpage>
<pub-id pub-id-type="doi">10.1016/j.neubiorev.2011.06.001</pub-id>
<pub-id pub-id-type="pmid">21693132</pub-id>
</element-citation>
</ref>
<ref id="CR24">
<label>24.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Robbins</surname>
<given-names>TW</given-names>
</name>
</person-group>
<article-title>Arousal systems and attentional processes</article-title>
<source/>Biol. Psychol.
          <year>1997</year>
<volume>45</volume>
<fpage>57</fpage>
<lpage>71</lpage>
<pub-id pub-id-type="doi">10.1016/S0301-0511(96)05222-2</pub-id>
<pub-id pub-id-type="pmid">9083644</pub-id>
</element-citation>
</ref>
<ref id="CR25">
<label>25.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schmitt</surname>
<given-names>JA</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Additional dopamine reuptake inhibition attenuates vigilance impairment induced by serotonin reuptake inhibition in man</article-title>
<source/>J. Psychopharmacol.
          <year>2002</year>
<volume>16</volume>
<fpage>207</fpage>
<lpage>214</lpage>
<pub-id pub-id-type="doi">10.1177/026988110201600303</pub-id>
<pub-id pub-id-type="pmid">12236626</pub-id>
</element-citation>
</ref>
<ref id="CR26">
<label>26.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ramaekers</surname>
<given-names>JG</given-names>
</name>
<name>
<surname>Muntjewerff</surname>
<given-names>ND</given-names>
</name>
<name>
<surname>O’Hanlon</surname>
<given-names>JF</given-names>
</name>
</person-group>
<article-title>A comparative study of acute and subchronic effects of dothiepin, fluoxetine and placebo on psychomotor and actual driving performance</article-title>
<source/>Br. J. Clin. Pharmacol.
          <year>1995</year>
<volume>39</volume>
<fpage>397</fpage>
<lpage>404</lpage>
<pub-id pub-id-type="doi">10.1111/j.1365-2125.1995.tb04468.x</pub-id>
<pub-id pub-id-type="pmid">7640146</pub-id>
</element-citation>
</ref>
<ref id="CR27">
<label>27.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>O’Hanlon</surname>
<given-names>JF</given-names>
</name>
<name>
<surname>Robbe</surname>
<given-names>HW</given-names>
</name>
<name>
<surname>Vermeeren</surname>
<given-names>A</given-names>
</name>
<name>
<surname>van Leeuwen</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Danjou</surname>
<given-names>PE</given-names>
</name>
</person-group>
<article-title>Venlafaxine’s effects on healthy volunteers’ driving, psychomotor, and vigilance performance during 15-day fixed and incremental dosing regimens</article-title>
<source/>J. Clin. Psychopharmacol.
          <year>1998</year>
<volume>18</volume>
<fpage>212</fpage>
<lpage>221</lpage>
<pub-id pub-id-type="doi">10.1097/00004714-199806000-00006</pub-id>
<pub-id pub-id-type="pmid">9617980</pub-id>
</element-citation>
</ref>
<ref id="CR28">
<label>28.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cote</surname>
<given-names>F</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Maternal serotonin is crucial for murine embryonic development</article-title>
<source/>Proc. Natl Acad. Sci. USA
          <year>2007</year>
<volume>104</volume>
<fpage>329</fpage>
<lpage>334</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.0606722104</pub-id>
<pub-id pub-id-type="pmid">17182745</pub-id>
</element-citation>
</ref>
<ref id="CR29">
<label>29.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yonan</surname>
<given-names>AL</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Bioinformatic analysis of autism positional candidate genes using biological databases and computational gene network prediction</article-title>
<source/>Genes, brain, Behav.
          <year>2003</year>
<volume>2</volume>
<fpage>303</fpage>
<lpage>320</lpage>
<pub-id pub-id-type="doi">10.1034/j.1601-183X.2003.00041.x</pub-id>
<pub-id pub-id-type="pmid">14606695</pub-id>
</element-citation>
</ref>
<ref id="CR30">
<label>30.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gabriele</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Sacco</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Persico</surname>
<given-names>AM</given-names>
</name>
</person-group>
<article-title>Blood serotonin levels in autism spectrum disorder: a systematic review and meta-analysis</article-title>
<source/>Eur. Neuropsychopharmacol.: J. Eur. Coll. Neuropsychopharmacol.
          <year>2014</year>
<volume>24</volume>
<fpage>919</fpage>
<lpage>929</lpage>
<pub-id pub-id-type="doi">10.1016/j.euroneuro.2014.02.004</pub-id>
</element-citation>
</ref>
<ref id="CR31">
<label>31.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Murphy</surname>
<given-names>DG</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Cortical serotonin 5-HT2A receptor binding and social communication in adults with Asperger’s syndrome: an in vivo SPECT study</article-title>
<source/>Am. J. psychiatry
          <year>2006</year>
<volume>163</volume>
<fpage>934</fpage>
<lpage>936</lpage>
<pub-id pub-id-type="doi">10.1176/ajp.2006.163.5.934</pub-id>
<pub-id pub-id-type="pmid">16648340</pub-id>
</element-citation>
</ref>
<ref id="CR32">
<label>32.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nakamura</surname>
<given-names>K</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Brain serotonin and dopamine transporter bindings in adults with high-functioning autism</article-title>
<source/>Arch. Gen. psychiatry
          <year>2010</year>
<volume>67</volume>
<fpage>59</fpage>
<lpage>68</lpage>
<pub-id pub-id-type="doi">10.1001/archgenpsychiatry.2009.137</pub-id>
<pub-id pub-id-type="pmid">20048223</pub-id>
</element-citation>
</ref>
<ref id="CR33">
<label>33.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chantiluke</surname>
<given-names>K</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Disorder-dissociated effects of fluoxetine on brain function of working memory in attention deficit hyperactivity disorder and autism spectrum disorder</article-title>
<source/>Psychological Med.
          <year>2015</year>
<volume>45</volume>
<fpage>1195</fpage>
<lpage>1205</lpage>
<pub-id pub-id-type="doi">10.1017/S0033291714002232</pub-id>
</element-citation>
</ref>
<ref id="CR34">
<label>34.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chantiluke</surname>
<given-names>K</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Inverse effect of fluoxetine on medial prefrontal cortex activation during reward reversal in ADHD and Autism</article-title>
<source/>Cereb. Cortex
          <year>2015</year>
<volume>25</volume>
<fpage>1757</fpage>
<lpage>1770</lpage>
<pub-id pub-id-type="doi">10.1093/cercor/bht365</pub-id>
<pub-id pub-id-type="pmid">24451919</pub-id>
</element-citation>
</ref>
<ref id="CR35">
<label>35.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Daly</surname>
<given-names>E</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Response inhibition and serotonin in autism: a functional MRI study using acute tryptophan depletion</article-title>
<source/>Brain
          <year>2014</year>
<volume>137</volume>
<fpage>2600</fpage>
<lpage>2610</lpage>
<pub-id pub-id-type="doi">10.1093/brain/awu178</pub-id>
<pub-id pub-id-type="pmid">25070512</pub-id>
</element-citation>
</ref>
<ref id="CR36">
<label>36.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Daly</surname>
<given-names>EM</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Serotonin and the neural processing of facial emotions in adults with autism: an fMRI study using acute tryptophan depletion</article-title>
<source/>Arch. Gen. Psychiatry
          <year>2012</year>
<volume>69</volume>
<fpage>1003</fpage>
<lpage>1013</lpage>
<pub-id pub-id-type="doi">10.1001/archgenpsychiatry.2012.513</pub-id>
<pub-id pub-id-type="pmid">22638012</pub-id>
</element-citation>
</ref>
<ref id="CR37">
<label>37.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lord</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Rutter</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Lecouteur</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Autism diagnostic interview-revised - a revised version of a diagnostic interview for caregivers of individuals with possible pervasive developmental disorders</article-title>
<source/>J. Autism Dev. Disord.
          <year>1994</year>
<volume>24</volume>
<fpage>659</fpage>
<lpage>685</lpage>
<pub-id pub-id-type="doi">10.1007/BF02172145</pub-id>
<pub-id pub-id-type="pmid">7814313</pub-id>
</element-citation>
</ref>
<ref id="CR38">
<label>38.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lord</surname>
<given-names>C</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Autism diagnostic observation schedule - a standardized observation of communicative and social-behavior</article-title>
<source/>J. Autism Dev. Disord.
          <year>1989</year>
<volume>19</volume>
<fpage>185</fpage>
<lpage>212</lpage>
<pub-id pub-id-type="doi">10.1007/BF02211841</pub-id>
<pub-id pub-id-type="pmid">2745388</pub-id>
</element-citation>
</ref>
<ref id="CR39">
<label>39.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wechsler</surname>
<given-names>D</given-names>
</name>
</person-group>
<article-title>The Psychometric tradition - developing the wechsler adult intelligence scale</article-title>
<source/>Contemp. Educ. Psychol.
          <year>1981</year>
<volume>6</volume>
<fpage>82</fpage>
<lpage>85</lpage>
<pub-id pub-id-type="doi">10.1016/0361-476X(81)90035-7</pub-id>
</element-citation>
</ref>
<ref id="CR40">
<label>40.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Baron-Cohen</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Wheelwright</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Skinner</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Martin</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Clubley</surname>
<given-names>E</given-names>
</name>
</person-group>
<article-title>The Autism-Spectrum Quotient (AQ): evidence from Asperger syndrome/high-functioning autism, males and females, scientists and mathematicians</article-title>
<source/>J. Autism Dev. Disord.
          <year>2001</year>
<volume>31</volume>
<fpage>5</fpage>
<lpage>17</lpage>
<pub-id pub-id-type="doi">10.1023/A:1005653411471</pub-id>
<pub-id pub-id-type="pmid">11439754</pub-id>
</element-citation>
</ref>
<ref id="CR41">
<label>41.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Foa</surname>
<given-names>EB</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The obsessive-compulsive inventory: development and validation of a short version</article-title>
<source/>Psychol. Assess.
          <year>2002</year>
<volume>14</volume>
<fpage>485</fpage>
<lpage>496</lpage>
<pub-id pub-id-type="doi">10.1037/1040-3590.14.4.485</pub-id>
<pub-id pub-id-type="pmid">12501574</pub-id>
</element-citation>
</ref>
<ref id="CR42">
<label>42.</label>
<mixed-citation publication-type="other">Barkley, R. M., Murphy, K. R. <italic>Attention Deficit Hyperactivity Disorder: A Clinical Workbook</italic> 3rd edn. (New York, Guilford, New York, 2005)</mixed-citation>
</ref>
<ref id="CR43">
<label>43.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hamilton</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>A rating scale for depression</article-title>
<source/>J. Neurol., Neurosurg., psychiatry
          <year>1960</year>
<volume>23</volume>
<fpage>56</fpage>
<lpage>62</lpage>
<pub-id pub-id-type="doi">10.1136/jnnp.23.1.56</pub-id>
<pub-id pub-id-type="pmid">14399272</pub-id>
</element-citation>
</ref>
<ref id="CR44">
<label>44.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hamilton</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>The assessment of anxiety states by rating</article-title>
<source/>Br. J. Med. Psychol.
          <year>1959</year>
<volume>32</volume>
<fpage>50</fpage>
<lpage>55</lpage>
<pub-id pub-id-type="doi">10.1111/j.2044-8341.1959.tb00467.x</pub-id>
<pub-id pub-id-type="pmid">13638508</pub-id>
</element-citation>
</ref>
<ref id="CR45">
<label>45.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sangkuhl</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Klein</surname>
<given-names>TE</given-names>
</name>
<name>
<surname>Altman</surname>
<given-names>RB</given-names>
</name>
</person-group>
<article-title>PharmGKB summary: citalopram pharmacokinetics pathway</article-title>
<source/>Pharmacogenetics genomics
          <year>2011</year>
<volume>21</volume>
<fpage>769</fpage>
<lpage>772</lpage>
<pub-id pub-id-type="doi">10.1097/FPC.0b013e328346063f</pub-id>
<pub-id pub-id-type="pmid">21546862</pub-id>
</element-citation>
</ref>
<ref id="CR46">
<label>46.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rubia</surname>
<given-names>K</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Tryptophan depletion reduces right inferior prefrontal activation during response inhibition in fast, event-related fMRI</article-title>
<source/>Psychopharmacol. (Berl.)
          <year>2005</year>
<volume>179</volume>
<fpage>791</fpage>
<lpage>803</lpage>
<pub-id pub-id-type="doi">10.1007/s00213-004-2116-z</pub-id>
</element-citation>
</ref>
<ref id="CR47">
<label>47.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lim</surname>
<given-names>L</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Neurofunctional abnormalities during sustained attention in severe childhood abuse</article-title>
<source/>PLoS ONE
          <year>2016</year>
<volume>11</volume>
<fpage>e0165547</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pone.0165547</pub-id>
<pub-id pub-id-type="pmid">27832090</pub-id>
</element-citation>
</ref>
<ref id="CR48">
<label>48.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Friedman</surname>
<given-names>NP</given-names>
</name>
<name>
<surname>Miyake</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>The relations among inhibition and interference control functions: a latent-variable analysis</article-title>
<source/>J. Exp. Psychol. Gen.
          <year>2004</year>
<volume>133</volume>
<fpage>101</fpage>
<lpage>135</lpage>
<pub-id pub-id-type="doi">10.1037/0096-3445.133.1.101</pub-id>
<pub-id pub-id-type="pmid">14979754</pub-id>
</element-citation>
</ref>
<ref id="CR49">
<label>49.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Brammer</surname>
<given-names>MJ</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Generic brain activation mapping in functional magnetic resonance imaging: a nonparametric approach</article-title>
<source/>Magn. Reson. imaging
          <year>1997</year>
<volume>15</volume>
<fpage>763</fpage>
<lpage>770</lpage>
<pub-id pub-id-type="doi">10.1016/S0730-725X(97)00135-5</pub-id>
<pub-id pub-id-type="pmid">9309607</pub-id>
</element-citation>
</ref>
<ref id="CR50">
<label>50.</label>
<mixed-citation publication-type="other">Talairach J. T. P. <italic>Co-planar stereotaxic atlas of the human brain</italic>. (Thieme, New York, 1988)</mixed-citation>
</ref>
<ref id="CR51">
<label>51.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Swick</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Ashley</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Turken</surname>
<given-names>AU</given-names>
</name>
</person-group>
<article-title>Left inferior frontal gyrus is critical for response inhibition</article-title>
<source/>BMC Neurosci.
          <year>2008</year>
<volume>9</volume>
<fpage>102</fpage>
<pub-id pub-id-type="doi">10.1186/1471-2202-9-102</pub-id>
<pub-id pub-id-type="pmid">18939997</pub-id>
</element-citation>
</ref>
<ref id="CR52">
<label>52.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Aron</surname>
<given-names>AR</given-names>
</name>
<name>
<surname>Poldrack</surname>
<given-names>RA</given-names>
</name>
</person-group>
<article-title>Cortical and subcortical contributions to Stop signal response inhibition: role of the subthalamic nucleus</article-title>
<source/>J. Neurosci.: Off. J. Soc. Neurosci.
          <year>2006</year>
<volume>26</volume>
<fpage>2424</fpage>
<lpage>2433</lpage>
<pub-id pub-id-type="doi">10.1523/JNEUROSCI.4682-05.2006</pub-id>
</element-citation>
</ref>
<ref id="CR53">
<label>53.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rubia</surname>
<given-names>K</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Mapping motor inhibition: conjunctive brain activations across different versions of go/no-go and stop tasks</article-title>
<source/>NeuroImage
          <year>2001</year>
<volume>13</volume>
<fpage>250</fpage>
<lpage>261</lpage>
<pub-id pub-id-type="doi">10.1006/nimg.2000.0685</pub-id>
<pub-id pub-id-type="pmid">11162266</pub-id>
</element-citation>
</ref>
<ref id="CR54">
<label>54.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rubia</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Smith</surname>
<given-names>AB</given-names>
</name>
<name>
<surname>Brammer</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Taylor</surname>
<given-names>E</given-names>
</name>
</person-group>
<article-title>Right inferior prefrontal cortex mediates response inhibition while mesial prefrontal cortex is responsible for error detection</article-title>
<source/>NeuroImage
          <year>2003</year>
<volume>20</volume>
<fpage>351</fpage>
<lpage>358</lpage>
<pub-id pub-id-type="doi">10.1016/S1053-8119(03)00275-1</pub-id>
<pub-id pub-id-type="pmid">14527595</pub-id>
</element-citation>
</ref>
<ref id="CR55">
<label>55.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Aron</surname>
<given-names>AR</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Inhibition of subliminally primed responses is mediated by the caudate and thalamus: evidence from functional MRI and Huntington’s disease</article-title>
<source/>Brain
          <year>2003</year>
<volume>126</volume>
<fpage>713</fpage>
<lpage>723</lpage>
<pub-id pub-id-type="doi">10.1093/brain/awg067</pub-id>
<pub-id pub-id-type="pmid">12566291</pub-id>
</element-citation>
</ref>
<ref id="CR56">
<label>56.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chambers</surname>
<given-names>CD</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Executive “brake failure” following deactivation of human frontal lobe</article-title>
<source/>J. Cogn. Neurosci.
          <year>2006</year>
<volume>18</volume>
<fpage>444</fpage>
<lpage>455</lpage>
<pub-id pub-id-type="pmid">16513008</pub-id>
</element-citation>
</ref>
<ref id="CR57">
<label>57.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Juan</surname>
<given-names>CH</given-names>
</name>
<name>
<surname>Muggleton</surname>
<given-names>NG</given-names>
</name>
</person-group>
<article-title>Brain stimulation and inhibitory control</article-title>
<source/>Brain Stimul.
          <year>2012</year>
<volume>5</volume>
<fpage>63</fpage>
<lpage>69</lpage>
<pub-id pub-id-type="doi">10.1016/j.brs.2012.03.012</pub-id>
<pub-id pub-id-type="pmid">22494830</pub-id>
</element-citation>
</ref>
<ref id="CR58">
<label>58.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Duann</surname>
<given-names>JR</given-names>
</name>
<name>
<surname>Ide</surname>
<given-names>JS</given-names>
</name>
<name>
<surname>Luo</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>CS</given-names>
</name>
</person-group>
<article-title>Functional connectivity delineates distinct roles of the inferior frontal cortex and presupplementary motor area in stop signal inhibition</article-title>
<source/>J. Neurosci.: Off. J. Soc. Neurosci.
          <year>2009</year>
<volume>29</volume>
<fpage>10171</fpage>
<lpage>10179</lpage>
<pub-id pub-id-type="doi">10.1523/JNEUROSCI.1300-09.2009</pub-id>
</element-citation>
</ref>
<ref id="CR59">
<label>59.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hampshire</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Chamberlain</surname>
<given-names>SR</given-names>
</name>
<name>
<surname>Monti</surname>
<given-names>MM</given-names>
</name>
<name>
<surname>Duncan</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Owen</surname>
<given-names>AM</given-names>
</name>
</person-group>
<article-title>The role of the right inferior frontal gyrus: inhibition and attentional control</article-title>
<source/>NeuroImage
          <year>2010</year>
<volume>50</volume>
<fpage>1313</fpage>
<lpage>1319</lpage>
<pub-id pub-id-type="doi">10.1016/j.neuroimage.2009.12.109</pub-id>
<pub-id pub-id-type="pmid">20056157</pub-id>
</element-citation>
</ref>
<ref id="CR60">
<label>60.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hu</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>CS</given-names>
</name>
</person-group>
<article-title>Neural processes of preparatory control for stop signal inhibition</article-title>
<source/>Hum. brain Mapp.
          <year>2012</year>
<volume>33</volume>
<fpage>2785</fpage>
<lpage>2796</lpage>
<pub-id pub-id-type="doi">10.1002/hbm.21399</pub-id>
<pub-id pub-id-type="pmid">21976392</pub-id>
</element-citation>
</ref>
<ref id="CR61">
<label>61.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Johnson</surname>
<given-names>KA</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Dissociation in performance of children with ADHD and high-functioning autism on a task of sustained attention</article-title>
<source/>Neuropsychologia
          <year>2007</year>
<volume>45</volume>
<fpage>2234</fpage>
<lpage>2245</lpage>
<pub-id pub-id-type="doi">10.1016/j.neuropsychologia.2007.02.019</pub-id>
<pub-id pub-id-type="pmid">17433378</pub-id>
</element-citation>
</ref>
<ref id="CR62">
<label>62.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>van der Meere</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Borger</surname>
<given-names>N</given-names>
</name>
<name>
<surname>van Os</surname>
<given-names>T</given-names>
</name>
</person-group>
<article-title>Sustained attention in major unipolar depression</article-title>
<source/>Percept. Mot. Skills
          <year>2007</year>
<volume>104</volume>
<fpage>1350</fpage>
<lpage>1354</lpage>
<pub-id pub-id-type="doi">10.2466/PMS.104.3.1350-1354</pub-id>
<pub-id pub-id-type="pmid">17879669</pub-id>
</element-citation>
</ref>
<ref id="CR63">
<label>63.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Taylor Tavares</surname>
<given-names>JV</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Distinct profiles of neurocognitive function in unmedicated unipolar depression and bipolar II depression</article-title>
<source/>Biol. psychiatry
          <year>2007</year>
<volume>62</volume>
<fpage>917</fpage>
<lpage>924</lpage>
<pub-id pub-id-type="doi">10.1016/j.biopsych.2007.05.034</pub-id>
<pub-id pub-id-type="pmid">17825802</pub-id>
</element-citation>
</ref>
<ref id="CR64">
<label>64.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rubia</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Smith</surname>
<given-names>AB</given-names>
</name>
<name>
<surname>Brammer</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Taylor</surname>
<given-names>E</given-names>
</name>
</person-group>
<article-title>Temporal lobe dysfunction in medication-naive boys with attention-deficit/hyperactivity disorder during attention allocation and its relation to response variability</article-title>
<source/>Biol. psychiatry
          <year>2007</year>
<volume>62</volume>
<fpage>999</fpage>
<lpage>1006</lpage>
<pub-id pub-id-type="doi">10.1016/j.biopsych.2007.02.024</pub-id>
<pub-id pub-id-type="pmid">17585887</pub-id>
</element-citation>
</ref>
<ref id="CR65">
<label>65.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rubia</surname>
<given-names>K</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Effects of age and gender on neural networks of motor response inhibition: from adolescence to mid-adulthood</article-title>
<source/>NeuroImage
          <year>2013</year>
<volume>83</volume>
<fpage>690</fpage>
<lpage>703</lpage>
<pub-id pub-id-type="doi">10.1016/j.neuroimage.2013.06.078</pub-id>
<pub-id pub-id-type="pmid">23845427</pub-id>
</element-citation>
</ref>
<ref id="CR66">
<label>66.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Krienen</surname>
<given-names>FM</given-names>
</name>
<name>
<surname>Buckner</surname>
<given-names>RL</given-names>
</name>
</person-group>
<article-title>Segregated fronto-cerebellar circuits revealed by intrinsic functional connectivity</article-title>
<source/>Cereb. Cortex
          <year>2009</year>
<volume>19</volume>
<fpage>2485</fpage>
<lpage>2497</lpage>
<pub-id pub-id-type="doi">10.1093/cercor/bhp135</pub-id>
<pub-id pub-id-type="pmid">19592571</pub-id>
</element-citation>
</ref>
<ref id="CR67">
<label>67.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jeong</surname>
<given-names>JW</given-names>
</name>
<name>
<surname>Chugani</surname>
<given-names>DC</given-names>
</name>
<name>
<surname>Behen</surname>
<given-names>ME</given-names>
</name>
<name>
<surname>Tiwari</surname>
<given-names>VN</given-names>
</name>
<name>
<surname>Chugani</surname>
<given-names>HT</given-names>
</name>
</person-group>
<article-title>Altered white matter structure of the dentatorubrothalamic pathway in children with autistic spectrum disorders</article-title>
<source/>Cerebellum
          <year>2012</year>
<volume>11</volume>
<fpage>957</fpage>
<lpage>971</lpage>
<pub-id pub-id-type="doi">10.1007/s12311-012-0369-3</pub-id>
<pub-id pub-id-type="pmid">22477362</pub-id>
</element-citation>
</ref>
<ref id="CR68">
<label>68.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Catani</surname>
<given-names>M</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Altered cerebellar feedback projections in Asperger syndrome</article-title>
<source/>NeuroImage
          <year>2008</year>
<volume>41</volume>
<fpage>1184</fpage>
<lpage>1191</lpage>
<pub-id pub-id-type="doi">10.1016/j.neuroimage.2008.03.041</pub-id>
<pub-id pub-id-type="pmid">18495494</pub-id>
</element-citation>
</ref>
<ref id="CR69">
<label>69.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Noonan</surname>
<given-names>SK</given-names>
</name>
<name>
<surname>Haist</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Muller</surname>
<given-names>RA</given-names>
</name>
</person-group>
<article-title>Aberrant functional connectivity in autism: evidence from low-frequency BOLD signal fluctuations</article-title>
<source/>Brain Res.
          <year>2009</year>
<volume>1262</volume>
<fpage>48</fpage>
<lpage>63</lpage>
<pub-id pub-id-type="doi">10.1016/j.brainres.2008.12.076</pub-id>
<pub-id pub-id-type="pmid">19401185</pub-id>
</element-citation>
</ref>
<ref id="CR70">
<label>70.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Khan</surname>
<given-names>AJ</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Cerebro-cerebellar resting-state functional connectivity in children and adolescents with Autism spectrum disorder</article-title>
<source/>Biol. psychiatry
          <year>2015</year>
<volume>78</volume>
<fpage>625</fpage>
<lpage>634</lpage>
<pub-id pub-id-type="doi">10.1016/j.biopsych.2015.03.024</pub-id>
<pub-id pub-id-type="pmid">25959247</pub-id>
</element-citation>
</ref>
</ref-list>
</back>
</article>
</pmc-articleset>